We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

French Researchers Discover How HIV Makes First Contact

Jun 1, 2001
Volume: 
10
Issue: 
6

SAN FRANCISCO—When the HIV virus is acquired through
breast-feeding or sexual activity, its first contact is with the epithelial
cells of the gastrointestinal, anorectal, or genitourinary tracts. It then
appears to use a raft mechanism and transcytosis to pass through the epithelial
cells to enter and infect the submucosal target cells, French researchers said
at the 40th Annual Meeting of the American Society for Cell Biology.

Morgane Bomsel, PhD, research director, Centre National de la
Recherche Scientifique (CNRS), working in the Institut Cochin de Genetique
Moleculaire, Paris, and her colleagues have shown that to enter epithelial
cells, HIV cells use envelope glycoprotein subunits gp-120 and gp-41 to bind to
galactosyl ceramide, a glycolipid receptor at the epithelial cell surface.

HIV passes through the epithelial cells without actually
infecting them. To do this, the virus uses a normal pathway called
transcytosis. During transcytosis, proteins or particles are taken into
vesicles in the epithelial cell, ferried through the cell, and released on the
other side into the host’s submucosal mononucleated target cells. The entire
process takes about 30 minutes.

The researchers suspected that to transport HIV, the epithelial
cells needed a stiff raft-like portion. To test this theory, they put
cholesterol-removing chemicals in sample epithelial cells. Since
cholesterol hardens membranes, the chemicals would eliminate the ability of the
cell to form the raft portion. Indeed, when these cells were then exposed to
HIV, the epithelial cells did not attach to or transport the virus.

Transcytosis of HIV was also blocked by treatments that
disrupted the lipid composition of galactosyl ceramide. "The structure of
this peptide is very important to the transport of HIV," Dr. Bomsel said.
HIV transcytosis thus depends on the membrane organization of raft microdomains
in epithelial cells that are stabilized by cholesterol, she concluded.

The researchers believe they may have found a way to block the
transcytosis of HIV and keep the virus from infecting healthy cells, using
treatments that block the action of the virus with galactosyl ceramide at the
epithelial cell surface.

They have discovered an antibody secreted in human mucosa that
binds specifically to a region in one of the HIV envelope subunits that bind to
galactosyl ceramide. "These antibodies, which are present in the mucosa of
HIV patients, neutralize the transport of HIV at the epithelial cell
surface," Dr. Bomsel said.

To be effective, such antibodies would have to be manufactured
in much larger quantities than normally present in the average person’s
mucosa. "We’re not sure exactly yet how to raise the levels of these
antibodies in vitro, but we are currently working on it," she said.
Annette Alfsen, MD, PhD, also of CNRS, was co-author of the paper.

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.